Beginner Reta Dosing: The 20 / 30 / 40 Unit Protocol

Dosing — 2026-05-08

Most researchers new to reta don't fail because they pick the wrong target dose — they fail because they jump to a target dose too fast and discontinue from GI side effects in week 2. The Phase 2 trial protocol starts at 2 mg weekly, but in practice many research programs use a gentler micro-titration into the 2 mg starting dose to give the gut more adaptation time. This article walks through the practical "20 / 30 / 40 unit" beginner protocol, why it works, and where it sits relative to the published trial schedule.

Quick note for researchers sourcing material: code WELCOME at checkout unlocks 35% off reta 10mg, 20mg, bacteriostatic water, and the Metabolic Stack. Every vial includes a batch-matched COA — variable potency between batches is the single biggest confounder in beginner titration studies.

The Protocol at a Glance

For a reta 10mg vial reconstituted with 2 mL of bacteriostatic water (yielding 5 mg/mL), this is the beginner ramp:

Once you're stable at 40 units (2.0 mg) for 3–4 weeks with no GI distress, you have a choice: hold at 40 units indefinitely (this dose alone produced meaningful effects in the Phase 2 4 mg-arm, when scaled) or begin the Phase 2 monthly titration to higher target doses.

Why 20 / 30 / 40 — The Logic

The Phase 2 trial used 2 mg weekly as the starting dose for all dose arms. That's the "reference" induction dose — below it, no published data exists; above it, GI side effects spike sharply.

The 20 / 30 / 40 ramp is slower than the trial protocol. Instead of jumping into 2 mg (40 units) on week 1, you spend two weeks below it — at 1 mg, then 1.5 mg — letting the gut adapt to GP-1 receptor signaling before reaching the trial-validated starting point.

Why this works:

• GP-1 receptor adaptation is real — the same dose that causes nausea in week 1 is asymptomatic by week 3
• The dominant adverse events (nausea, vomiting, diarrhea) are dose-dependent AND introduction-dependent
• Reaching 2 mg via three steps instead of one starting point reduces peak GI severity
• The cost is two extra weeks before "real" induction begins — typically a worthwhile tradeoff for new researchers

Phase 2 trial subjects had support infrastructure — clinical staff, anti-emetic protocols, weekly check-ins. Most independent research protocols don't, which justifies a gentler ramp.

Reconstitution: The Math That Makes This Work

These unit numbers depend on a specific reconstitution. If you change the bac water volume, you change the per-unit dose. The standard:

• Vial: Reta 10mg lyophilized
• Diluent: 2 mL bacteriostatic water (0.9% benzyl alcohol)
• Final concentration: 5 mg/mL
• Per unit (on U-100 syringe): 0.05 mg

So: - 20 units × 0.05 mg = 1.0 mg - 30 units × 0.05 mg = 1.5 mg - 40 units × 0.05 mg = 2.0 mg

For the 20mg vial, double the bac water to 4 mL to keep the same 5 mg/mL concentration and the same unit math. That vial gives you ~10 weekly doses at 2 mg, which covers weeks 3–12 of a beginner protocol with comfortable buffer.

If you reconstitute at a different concentration (e.g., 10 mg/mL with 1 mL bac water), the unit math changes. The protocol numbers above only work at 5 mg/mL. See our reconstitution guide for general technique.

Once-Weekly, Same Day, Subcutaneous

All Phase 2 reta trials used once-weekly subcutaneous administration. The peptide's albumin-binding fatty acid chain gives it a half-life of approximately 6 days, so weekly dosing produces near-steady-state exposure.

Practical pointers:

• Pick a consistent day of the week and stick with it. Doses 5–8 days apart are fine; doses 3–4 days apart double-dose the active drug.
• Subcutaneous, into abdominal fat or thigh. Rotate sites week to week.
• Refrigerate the reconstituted vial. Lyophilized at -20°C; reconstituted at 2–8°C, stable for 28 days under bacteriostatic water.
• Inject in the evening if GI side effects are a concern — sleeping through the peak nausea window is easier than working through it.

What to Expect Week by Week

Weeks 1–2 (20 → 30 units) - Mild nausea is common, especially after the first injection - Appetite suppression is real but modest - Weight changes are minimal — this is induction, not therapeutic dose - Watch for: vomiting (rare at this dose; if persistent, hold at 20 units for an extra week)

Week 3 onward (40 units / 2.0 mg) - This is the trial-validated starting dose - Appetite suppression noticeably stronger - Modest weight changes begin to appear by week 4–6 - GI side effects typically peak in the first 7 days at this dose, then resolve

Beyond week 6 - Most beginners hold at 40 units indefinitely — the 4 mg-arm of the Phase 2 trial still produced ~17% weight loss - Researchers targeting larger effects can transition to the Phase 2 monthly titration schedule — 4 mg at week 5–8, 6 mg at week 9–12, etc. - The 8 mg dose has a near-equivalent endpoint to 12 mg with substantially better tolerability — this is where most non-trial research protocols end up

When to Hold, When to Step Down

The protocol is gentle, but individual responses vary. Hold at the current dose (don't escalate next week) if:

• Nausea is severe (vomiting more than once on injection day)
• Diarrhea is persistent (more than 3 days after dose)
• You miss a dose by more than 4 days
• You're sick (any acute illness — wait until recovered)

Step down (reduce to the previous week's dose) if:

• Holding for 2 weeks doesn't resolve the issue
• Any concerning symptom persists (severe abdominal pain, signs of pancreatitis, jaundice)
• You're planning a procedure or anesthesia in the coming 2–3 weeks

There's no penalty for taking longer to ramp. The endpoint is the same; the timeline is different.

Storage and Vial Hygiene

• Lyophilized vial: Store at -20°C for long-term stability; refrigerated (2–8°C) is acceptable for several months
• Reconstituted vial: Refrigerated (2–8°C), 28-day shelf life under bacteriostatic water
• Use alcohol swabs on the rubber stopper before each draw
• Inspect for cloudiness or particulates before each dose — clear solution only

For longer protocols, our peptide storage guide covers freeze-thaw cycles and stability extension.

When This Protocol Isn't Right

The 20/30/40 ramp is for researchers new to GP-class compounds. It's not the right protocol if:

• The research design specifically requires the Phase 2 trial schedule (use the published 2 mg / 4 mg / 6 mg / 8 mg / 10 mg / 12 mg ramp)
• The endpoint requires reaching 8 mg or 12 mg by a specific timepoint (the gentle ramp adds 2 weeks to the timeline)
• The subject has prior GP-class experience and known tolerability — they can start directly at 2 mg
• The subject has T2D and the protocol is glycemic-primary (sema may be the better fit; see our reta vs Ozempic comparison)

Sourcing for the Protocol

A 12-week beginner protocol uses: - 2 vials of reta 10mg (or 1 vial of reta 20mg) - 1 vial of bacteriostatic water 10mL - A few standard U-100 insulin syringes

The Metabolic Stack (Reta 20mg + Tesamorelin 10mg) is the cleanest entry point for researchers also studying body composition rather than body weight alone — see our reta vs tesamorelin discussion for the stacking rationale.

Use code WELCOME at checkout for 35% off reta 10mg, reta 20mg, bacteriostatic water, and the Metabolic Stack. Every vial ships with a batch-matched COA showing 99%+ HPLC purity, US-based handling, and same-batch consistency for multi-vial protocols.

Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.